KAISA HEALTH(00876)

Search documents
佳兆业健康(00876) - 2024 - 年度业绩
2024-08-02 10:29
Fund Utilization - The net proceeds from the rights issue amounting to HKD 507,160,000 have been fully utilized as of December 31, 2023[1]. - Approximately HKD 246,000,000 was allocated for investments in the Chinese healthcare industry[1]. - Around HKD 164,160,000 was used to seek suitable investment opportunities[1]. - HKD 97,000,000 was dedicated to the continued development of the dental business[1]. Dental Business Expenditure - For the fiscal year ending December 31, 2023, HKD 5,050,000 was specifically used for the dental business[2]. - The breakdown of the HKD 5,050,000 includes HKD 3,196,000 for operating costs, HKD 1,604,000 for product R&D, and HKD 250,000 for marketing[2]. Investment Valuation - The fair value of significant investments in Zhuhai Jinyiming Equity Investment Fund Partnership and Haoyikang Health Services (Shenzhen) Partnership is HKD 144,000,000 and HKD 49,100,000 respectively[3]. - These investments represent approximately 23.8% and 8.1% of the total assets as of December 31, 2023[3]. - The previously reported percentages for these investments were corrected from 74.6% and 25.4%[3]. - All other information in the annual report remains unchanged despite these clarifications[3].
佳兆业健康(00876) - 2023 - 年度财报
2024-04-29 09:00
Financial Performance - The company recorded revenue of approximately HKD 185.9 million for the year ended December 31, 2023, a decrease of 2.9% compared to HKD 191.5 million in 2022[5]. - The net profit attributable to shareholders was approximately HKD 7.47 million, a significant improvement from a loss of HKD 123.3 million in 2022, resulting in earnings per share of HKD 0.15 compared to a loss per share of HKD 2.45 in the previous year[5]. - The group's revenue for the year ended December 31, 2023, was approximately HKD 185.9 million, a decrease of 2.9% compared to HKD 191.5 million for the year ended December 31, 2022[28]. - The profit attributable to shareholders for the year was approximately HKD 7.47 million, with basic earnings per share of HKD 0.15, compared to a loss of approximately HKD 123.3 million and basic loss per share of HKD 2.45 in 2022[28]. - The gross profit for the year was HKD 81,100,000, a decrease of approximately HKD 1,500,000 compared to HKD 82,600,000 in 2022, primarily due to a decline in selling prices in mainland China[29]. - The gross profit margin increased to 43.6%, up from 43.1% in 2022, reflecting a higher revenue proportion from the dental business segment[29]. Dental Business Development - The dental business continues to show stable revenue growth, with over 2,200 partnerships established with major hospitals and dental institutions across China[6]. - The company plans to expand its dental business both domestically and internationally, including increasing production capacity in China and developing high-end dental products with cosmetic functions[9]. - Future strategies include establishing a dental implant production facility in Chengdu to reduce production costs and support large-scale manufacturing[9]. - The group has expanded its dental implant R&D team and received acceptance for more implant size registration applications, leading to significant growth in the implant business in 2023[18]. - The group plans to enhance its dental business by expanding sales networks domestically and internationally, particularly in the U.S., and developing high-end dental products[25]. - The overall market for dental medicine in China is expected to release significant growth potential, providing long-term sustainable development opportunities for the company[10]. Rehabilitation Business Development - The rehabilitation business has established four outpatient clinics in Shenzhen, focusing on post-operative recovery and sports injury rehabilitation, amidst a competitive market landscape[7]. - The company aims to enhance its brand reputation through refined operations and professional development in the rehabilitation sector, while also introducing medical product designs to improve performance[10]. - The rehabilitation business will focus on improving rehabilitation products and service levels in response to increasing competition in the market[27]. Research and Development - Research and development expenses for the year were approximately HKD 16.8 million, reflecting the management's commitment to investing in future technologies[18]. - The company is committed to increasing R&D investment and introducing skilled professionals to meet the growing demand for dental healthcare[10]. Corporate Governance - The company has a commitment to corporate governance with independent directors ensuring transparency and accountability in decision-making processes[54][56]. - The board includes independent directors with diverse expertise, such as Dr. Liu Yanwen in technology economics and Dr. Lv Aiping in traditional Chinese medicine, which supports the company's strategic development[54][56]. - The company emphasizes the importance of effective corporate governance as a key factor for maintaining development and enhancing shareholder value[62]. - The board consists of a balanced mix of executive and independent non-executive directors, ensuring compliance with listing rules regarding independence[67]. - The company has complied with the corporate governance code, except for the absence of an internal audit function, which is reviewed annually[62]. Environmental, Social, and Governance (ESG) Initiatives - The environmental, social, and governance (ESG) report covers the performance of subsidiaries that account for over 90% of the group's total revenue[123]. - The report adheres to the guidelines set by the Hong Kong Stock Exchange for ESG reporting, ensuring compliance and transparency[124]. - The group aims to manage the environmental and social impacts of its operations while fulfilling its responsibilities to enhance sustainability and transparency[130]. - The company encourages stakeholder feedback on ESG policies and performance, highlighting its commitment to continuous improvement[128]. - The company identified 21 key ESG issues based on their importance to stakeholders and business development[137]. Employee Management and Safety - The company has a total of 893 employees with an overall employee turnover rate of approximately 39.7%[170]. - The company has implemented a safety training program, resulting in zero work-related fatalities and zero lost workdays due to injuries in 2023[174]. - The company conducts annual medical examinations for employees engaged in hazardous work[174]. - The company has a policy to ensure equal opportunities and prevent discrimination based on various factors, including gender and age[166]. Risk Management - The group has identified and assessed significant risks that could threaten the achievement of its business objectives[105]. - The internal control system has been deemed effective and sufficient during the year[105]. - The board will conduct at least an annual review of the adequacy and effectiveness of the group's risk management and internal control systems[104].
佳兆业健康(00876) - 2023 - 年度业绩
2024-03-25 14:55
Financial Performance - Total revenue for the year ended December 31, 2023, was HKD 185,882,000, a decrease of 2.9% from HKD 191,499,000 in 2022[4] - Gross profit for the same period was HKD 81,073,000, down from HKD 82,565,000, reflecting a gross margin of approximately 43.6%[4] - The company reported a net profit of HKD 6,150,000 for 2023, a significant recovery from a net loss of HKD 172,132,000 in 2022[4] - Basic earnings per share for 2023 was HKD 0.15, compared to a loss per share of HKD 2.45 in the previous year[5] - The total comprehensive income for the year was HKD 7,343,000, a turnaround from a comprehensive loss of HKD 214,482,000 in 2022[5] - The company's profit before tax decreased from HKD 23,123,000 in 2022 to HKD 18,105,000 in 2023, representing a decline of approximately 21.6%[22] - Total employee costs reduced from HKD 127,341,000 in 2022 to HKD 119,605,000 in 2023, a decrease of about 6.1%[22] - The profit attributable to shareholders for the year was approximately HKD 7.47 million, with basic earnings per share of HKD 0.15, compared to a loss of approximately HKD 123.3 million and basic loss per share of HKD 2.45 in the previous year[49] Assets and Liabilities - Non-current assets decreased to HKD 249,646,000 in 2023 from HKD 291,473,000 in 2022, primarily due to impairments and disposals[6] - Current assets totaled HKD 355,421,000, down from HKD 476,125,000 in the previous year, with a notable reduction in trade and other receivables[6] - The company’s total equity increased to HKD 491,764,000 in 2023 from HKD 470,906,000 in 2022, indicating improved financial stability[7] - As of December 31, 2023, the total reportable segment assets amounted to HKD 603,461,000, with the dental business holding HKD 325,881,000 and the health business holding HKD 277,580,000[17] - The total reportable segment liabilities were HKD 91,798,000, with the dental business liabilities at HKD 66,117,000 and health business liabilities at HKD 25,681,000[17] - The fair value of financial assets decreased from HKD 200,280,000 in 2022 to HKD 193,114,000 in 2023, a decline of about 3.3%[29] - The expected credit loss provision for trade receivables increased to HKD 2,413,000 in 2023 from HKD 2,048,000 in 2022, with a net charge of HKD 1,595,000 recognized during the year[32] - Trade payables decreased to HKD 26,773,000 in 2023 from HKD 46,552,000 in 2022, with the aging analysis indicating a significant increase in payables due within 0 to 90 days[36] Business Segments - For the fiscal year ending December 31, 2023, the total revenue generated from external customers was HKD 185,882,000, with the dental business contributing HKD 179,441,000 and the health business contributing HKD 6,441,000[15] - The operating profit before depreciation and amortization for the dental business was HKD 13,152,000, while the health business reported an operating loss of HKD 23,861,000, resulting in a total operating loss of HKD 10,709,000[15] - The health business reported a significant operating loss of HKD 31,222,000 for the fiscal year ending December 31, 2023, compared to an operating loss of HKD 50,129,000 in the previous year[15][16] - Revenue from the dental business was approximately HKD 179.4 million, a decrease of about HKD 1.9 million from HKD 181.3 million in the previous year[51] Research and Development - Research and development expenses slightly decreased from HKD 17,428,000 in 2022 to HKD 16,835,000 in 2023, a reduction of about 3.4%[22] - The group received government subsidies and other income related to research and development amounting to approximately HKD 2 million[53] - The company has applied for a super deduction allowance for R&D expenses, allowing a 175% deduction for tax purposes[24] - The group aims to achieve significant growth in its implant business, with expectations for more product approvals in 2024[61] Future Plans and Strategies - The company plans to continue focusing on market expansion and new product development to drive future growth[3] - The group plans to expand its sales network in both domestic and overseas markets, including the United States, and enhance production capacity in China[60] - The group is actively seeking investment and collaboration opportunities in high-tech dental fields to enhance cross-selling opportunities[60] - The company plans to enhance shareholder value by expanding its dental and health businesses, focusing on advanced technology and high-end dental materials[58] Corporate Governance and Compliance - The company expects that the revised Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements in the foreseeable future[12] - The audit committee reviewed the group's internal controls, risk management systems, and accounting standards for the year ending December 31, 2023[85] - The group has complied with the corporate governance code, except for the absence of an internal audit function[83] - The group has adopted a stock option plan as a long-term incentive for directors and eligible employees[79] Employee and Operational Information - As of December 31, 2023, the group employed approximately 893 employees, a decrease from about 940 employees as of December 31, 2022[79] - The group operates a mandatory provident fund scheme for eligible employees in Hong Kong, with contributions made by both employer and employees[79] Dividends and Shareholder Information - The company has not declared or proposed any dividends for the years ended December 31, 2023, and 2022[26] - The board did not recommend a final dividend for the year ending December 31, 2023[50] - The annual results announcement is available on the company's website and will be sent to shareholders[87] - The group expresses gratitude to shareholders, customers, suppliers, and the banking sector for their support over the past year[89]
佳兆业健康(00876) - 2023 - 中期财报
2023-09-26 08:42
Financial Performance - Total revenue for the six months ended June 30, 2023, was HKD 92,590,000, a decrease of 1.5% compared to HKD 93,979,000 in the same period of 2022[13] - Gross profit for the same period was HKD 38,560,000, down from HKD 39,933,000, reflecting a decline of 3.4%[13] - The company reported a net profit of HKD 38,776,000 for the six months, a significant recovery from a loss of HKD 120,631,000 in the prior year[14] - Earnings per share for the period was HKD 0.79, compared to a loss per share of HKD 1.92 in the previous year[14] - Other income and gains increased to HKD 21,475,000, up from HKD 6,538,000, marking a growth of 228%[13] - The company recorded a gain of HKD 67,861,000 from the sale of subsidiaries, contributing positively to the overall financial performance[13] - The total comprehensive income for the period was HKD 15,058,000, a recovery from a comprehensive loss of HKD 142,457,000 in the same period last year[14] - The company reported a loss of HKD 97.0 million for the first half of 2023, compared to a loss of HKD 387.4 million in the same period of 2022[19] - The group reported a pre-tax profit of HKD 40,001,000 for the six months ended June 30, 2023, compared to a loss of HKD 97,017,000 in the same period of 2022[42] Expenses and Liabilities - Administrative expenses decreased significantly to HKD 25,350,000 from HKD 47,567,000, a reduction of 46.6%[13] - The company experienced a foreign exchange loss of HKD 18,907,000, compared to a loss of HKD 21,826,000 in the previous year[14] - Non-current liabilities decreased from HKD 25.7 million to HKD 14.1 million, a reduction of about 45%[17] - The total liabilities decreased significantly from HKD 271.0 million to HKD 94.5 million, a reduction of about 65.1%[16] - The total amount of trade and other payables decreased significantly to HKD 65,742,000 as of June 30, 2023, from HKD 123,995,000 as of December 31, 2022, indicating a reduction of 46.9%[56] Assets and Equity - As of June 30, 2023, total assets amounted to HKD 809.8 million, a decrease from HKD 967.6 million as of December 31, 2022, representing a decline of approximately 16.3%[16] - The company's net asset value increased to HKD 500.7 million from HKD 470.9 million, reflecting an increase of approximately 6.1%[17] - The total equity attributable to equity holders of the company increased to HKD 500.8 million from HKD 485.3 million, an increase of approximately 3.1%[19] - The net current assets as of June 30, 2023, were approximately HKD 234,600,000, up from HKD 205,100,000 as of December 31, 2022[112] Revenue Breakdown - For the six months ended June 30, 2023, the total revenue generated from external customers was HKD 92,590,000, with contributions from dental business (HKD 88,765,000), health rehabilitation (HKD 2,184,000), and health care (HKD 1,641,000) [29] - Revenue from China (excluding Hong Kong) for the six months ended June 30, 2023, was HKD 92,256,000, a decrease of 1.1% compared to HKD 93,269,000 in 2022[34] - Revenue from the dental business was approximately HKD 88.8 million, an increase of about HKD 1.1 million compared to HKD 87.7 million in the same period last year[91] Research and Development - Research and development expenses for the six months ended June 30, 2023, were HKD 8,522,000, down 14.8% from HKD 10,000,000 in 2022[38] - Research and development expenses for the dental business were approximately HKD 8.5 million, down from HKD 10 million in the same period last year[93] - The company has expanded its R&D team for implant technology, with new product registrations being processed by the National Medical Products Administration[93] Future Plans and Strategies - The company plans to focus on market expansion and new product development to drive future growth[12] - The group plans to expand its dental business by increasing sales networks domestically and overseas, particularly in the U.S., and developing high-end dental products with cosmetic functions[99] - The rehabilitation business is exploring community rehabilitation models and plans to attempt brand licensing for 1-2 community rehabilitation centers in the second half of 2023[101] - The group anticipates continued rapid growth in its implant business in the second half of the year, following strong performance in the first half[100] Shareholder Information - The average number of ordinary shares issued during the period was 5,042,139,374, resulting in basic and diluted earnings per share of HKD 0.0079 for 2023[43] - The number of issued ordinary shares remained at 5,042,139,374 as of June 30, 2023, unchanged from December 31, 2022[113] - The company has a share option plan that allows for the issuance of shares up to 30% of the company's total issued shares[143] Other Financial Information - The company recognized share-based payment expenses of HKD 1,646,000 for the six months ended June 30, 2023, compared to HKD 785,000 for the same period in 2022[73] - The company had no net debt as of June 30, 2023, and therefore did not calculate the capital debt ratio[113] - The group has no contingent liabilities as of June 30, 2023, maintaining a stable financial position[110]
佳兆业健康(00876) - 2022 - 年度财报
2023-04-28 08:46
Financial Performance - The company reported revenue of approximately HKD 191.5 million for the year ended December 31, 2022, a decrease of 8.65% compared to HKD 209.6 million in 2021[5]. - The loss attributable to shareholders was approximately HKD 123.3 million, translating to a basic loss per share of HKD 0.0245, compared to a profit of HKD 2.4 million and earnings per share of HKD 0.0005 in 2021[5][17]. - The company does not recommend a dividend for the year due to the reported losses[5]. - Gross profit for the year was HKD 82.6 million, down from HKD 97.4 million in the previous year, resulting in a gross margin decrease to 43.1% from 46.5%[35]. - The company's revenue for the year slightly decreased due to the ongoing adverse effects of the COVID-19 pandemic, with total sales impacted[34]. Business Expansion and Development - The dental business continues to grow steadily, with a sales service network covering major cities in China and partnerships with over 2,000 institutions[6]. - The company plans to expand its sales network in both domestic and overseas markets, including the United States, and increase production capacity in China[10]. - The newly launched transparent aligners have shown strong performance in driving revenue growth[10]. - The rehabilitation business is expanding with three clinics operating in key districts of Shenzhen, focusing on various rehabilitation services[8][12]. - The company plans to open 1-2 community rehabilitation centers in 2023, leveraging community resources from the Kaisa Group to expand its market presence in South China[32]. Research and Development - Research and development expenditure for the dental business was HKD 17.4 million in 2022, slightly up from HKD 17.2 million in 2021, indicating a commitment to future technology investment[20]. - The company has applied for 9 new patents and completed 3 medical device import registration certificates in China, enhancing its research and development capabilities[21]. - Research and development expenses are focused on enhancing future product competitiveness, including investments in 3D printing technology and invisible orthodontics software[38]. - The company aims to enhance R&D investment and innovation, introducing high-value products to meet growing dental and rehabilitation needs[145]. Health Business Performance - The health business incurred an operating loss of approximately HKD 32.4 million for the year ended December 31, 2022, due to delays in development plans caused by the COVID-19 pandemic[23]. - The company recorded an impairment loss of approximately HKD 73.4 million related to right-of-use assets, properties, and equipment in the health business for the year ended December 31, 2022[23]. - The company expects to generate a contract sales scale of RMB 160 million in 2023 from the health business, driven by the integration of organic agriculture, tourism, and health services[31]. Corporate Governance - The company emphasizes effective corporate governance as a key factor for maintaining development and enhancing shareholder value[72]. - The board has not authorized any other significant investments or additional capital asset plans as of the report date[54]. - The company has engaged an independent international auditing firm for annual internal control audits, despite lacking an internal audit function[72]. - The company has established three committees: the nomination committee, remuneration committee, and audit committee to oversee specific areas of governance[103]. - The board is responsible for maintaining an effective internal control system, which was reviewed by an independent international auditing firm for the year ended December 31, 2022[110]. Environmental, Social, and Governance (ESG) Initiatives - Kaisa Health Group reported a commitment to sustainable development, integrating ESG responsibilities into its core business operations[143]. - The company aims to create long-term value for stakeholders while fulfilling environmental and social responsibilities[145]. - The board is responsible for assessing and determining ESG-related risks and opportunities, ensuring effective risk management and internal control systems[149]. - The company achieved a waste reduction, with non-hazardous waste decreasing to 5.5 tons in 2022 from 64.4 tons in 2021, a reduction of 91.5%[166]. - The company strictly adhered to various environmental laws and regulations during the reporting period, including the Environmental Protection Law and the Air Pollution Prevention Law[167]. Employee Management and Safety - The group had approximately 940 employees across Hong Kong, China, and the United States as of December 31, 2022, an increase from approximately 700 employees in the previous year[55]. - The company has established a "Fair Treatment Policy" to promote equality among employees regardless of ethnicity, gender, or other protected statuses[185]. - The company has a zero fatality rate from occupational accidents over the past three years[191]. - The company provided training to 93% of male employees and 100% of female employees, with an average training duration of 6.8 hours for males and 6.3 hours for females[194]. - The company has implemented a comprehensive employee safety training program, including regular fire drills and emergency response training[190]. Supply Chain Management - The group collaborates with 72 suppliers in China and 1 supplier in North America[198]. - All suppliers must sign a Social Responsibility Management Commitment to meet environmental and labor standards[197]. - Suppliers are required to complete an Environmental Factors Survey to assess their operational impact on the environment[197]. - The group prioritizes suppliers with minimal negative environmental impact and those certified in ISO14001, ISO9001, and OSHMS[197].
佳兆业健康(00876) - 2022 - 年度业绩
2023-03-28 13:02
香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本公佈全部或任何部 份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 Kaisa Health Group Holdings Limited 佳 兆 業 健 康 集 團 控 股 有 限 公 司 (於百慕達註冊成立之有限公司) (股份代號:876) 全年業績公佈 截至二零二二年十二月三十一日止年度 佳兆業健康集團控股有限公司(「本公司」)董事(「董事」)會(「董事會」)欣然公佈本 公司及其附屬公司(統稱為「本集團」)截至二零二二年十二月三十一日止年度之經 審核綜合業績,連同截至二零二一年十二月三十一日止相應年度之比較數字。 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收益 3 191,499 209,626 銷售成本 (108,934) (112,211) 毛利 82,565 97,415 其他收入、收益及虧損 8,958 12,859 銷售及分銷成本 (46,098) (49,143) 行政支出 (86,445 ...
佳兆业健康(00876) - 2022 - 中期财报
2022-09-29 09:00
Financial Performance - Total revenue for the six months ended June 30, 2022, was HKD 93,979,000, a decrease of 9.4% from HKD 103,275,000 in the same period of 2021[13] - Gross profit for the same period was HKD 39,933,000, down 26.2% from HKD 54,058,000 year-on-year[13] - The company reported a loss before tax of HKD 120,432,000, compared to a profit of HKD 58,235,000 in the previous year[13] - The total comprehensive loss for the period was HKD 142,457,000, compared to a comprehensive income of HKD 65,279,000 in the same period last year[13] - For the six months ended June 30, 2022, the company reported a loss attributable to equity holders of HKD 97,017,000, compared to a profit of HKD 60,666,000 in the same period of 2021, representing a significant decline[14] - The total comprehensive loss attributable to equity holders for the same period was HKD 120,127,000, compared to a total comprehensive income of HKD 66,496,000 in 2021[14] - Basic and diluted loss per share for the six months ended June 30, 2022, was HKD 1.92, a decrease from earnings of HKD 1.20 per share in the prior year[14] Assets and Liabilities - As of June 30, 2022, non-current assets totaled HKD 333,981,000, down from HKD 395,499,000 as of December 31, 2021, indicating a decrease of approximately 15.5%[16] - Current assets decreased to HKD 506,324,000 from HKD 575,834,000, reflecting a decline of about 12.0%[16] - The company's total liabilities increased to HKD 272,259,000 from HKD 261,991,000, showing a rise of approximately 3.9%[17] - The net asset value as of June 30, 2022, was HKD 542,033,000, down from HKD 682,844,000 at the end of 2021, representing a decrease of about 20.6%[17] - The company reported a decrease in cash and cash equivalents to HKD 202,447,000 from HKD 259,264,000, a decline of approximately 22.0%[16] - The company’s total equity attributable to equity holders was HKD 532,636,000, down from HKD 651,117,000, indicating a decrease of about 18.2%[17] Operational Segments - Total revenue generated from external customers was HKD 93,979 thousand, with the dental business contributing HKD 87,658 thousand[28] - The operating loss for the health and rehabilitation segment was HKD (3,678) thousand, while the health and wellness segment reported an operating loss of HKD (28,307) thousand[28] - The company has expanded its operational segments to include health and wellness, with new projects in Zhuhai and Shanghai commencing operations[28] - The segment profit before depreciation and amortization for the health rehabilitation segment was HKD 15,280,000, while the health maintenance segment reported a profit of HKD 45,829,000, leading to a total segment profit of HKD 55,370,000[53] Cash Flow - For the six months ended June 30, 2022, the net cash used in operating activities was HKD (51,669) thousand, compared to HKD 52,320 thousand for the same period in 2021[21] - The net cash generated from investing activities was HKD 6,314 thousand, a decrease from HKD 8,842 thousand in the previous year[21] - The net cash used in financing activities was HKD (6,322) thousand, compared to HKD (4,273) thousand in the same period last year[21] Research and Development - Research and development expenses for the period were HKD 10,000,000, an increase from HKD 8,892,000 in the previous year, reflecting a growth of approximately 12.4%[65] - The company applied for 9 new patents as part of its ongoing expansion of the implant research and development team[156] - Government grants and other income related to training consultations for research and development were approximately HKD 1.2 million for the six months ended June 30, 2022[156] Market and Strategic Outlook - Future outlook remains cautious due to ongoing market challenges and the need for strategic adjustments[13] - The company is actively adjusting its marketing strategies in response to significant impacts from the COVID-19 pandemic on customer orders[152] - The company plans to expand its dental business by increasing sales networks both domestically and internationally, particularly in the U.S.[163] - The dental market in China is expected to have significant growth potential, with the company aiming to enhance its product offerings and market presence[163] Impairment and Losses - The company experienced a significant loss in fair value changes of financial assets amounting to HKD 13,891,000, compared to a gain of HKD 47,609,000 in the previous year[13] - The impairment loss on trade receivables was HKD 1,666,000, compared to a reversal of HKD 138,000 in the previous year[13] - Impairment losses of approximately HKD 45,300,000 were recognized for right-of-use assets, properties, and equipment in the health business segment for the same period[157] Shareholder Information - The company has not declared or recommended any dividends for the six months ended June 30, 2022[70] - The average number of ordinary shares in issue during the period remained unchanged at 5,042,139,374 shares[73] - The company recognized share-based payment expenses of HKD 1,646,000 for the six months ended June 30, 2022, compared to HKD 3,600,000 for the same period in 2021[131] Employment and Staff - The group employed approximately 800 staff as of June 30, 2022, an increase from approximately 700 staff as of December 31, 2021[183]
佳兆业健康(00876) - 2021 - 年度财报
2022-04-29 08:39
Financial Performance - The company recorded revenue of approximately HKD 209.6 million for the year ended December 31, 2021, representing a 14.04% increase from HKD 183.8 million in 2020[5] - The net profit attributable to shareholders was HKD 2.4 million, a significant recovery from a loss of HKD 39.7 million in the previous year[5] - The group's revenue for the year reached approximately HKD 209.6 million, an increase of 14.04% compared to HKD 183.8 million in the previous year[20] - The net profit attributable to shareholders was approximately HKD 2.4 million, with basic earnings per share of HKD 0.05, a recovery from a loss of HKD 39.7 million and basic loss per share of HKD 0.79 in the previous year[20] - The company's gross profit for the year was HKD 97.4 million, an increase of approximately HKD 7.4 million from the previous year, with a gross margin of 46.5%[41] Business Expansion and Acquisitions - The company acquired 100% of Basic Dental, which owns the BIOTANIUM dental implant brand, enhancing its product offerings in the dental sector[7] - The group acquired 100% of Basic Dental Implant System, Inc., entering the high-value dental implant market, which has significant growth potential[24] - The company anticipates that the Shili Lianjiang project will contribute approximately RMB 250 million in contract sales starting in 2022[12] - The company plans to expand its rehabilitation services in Shenzhen and potentially extend these services to other core cities in the Greater Bay Area[14] - The company aims to enhance its dental business by expanding its sales network domestically and internationally, particularly in the U.S.[11] Research and Development - Research and development expenditure decreased to HKD 17.2 million from HKD 20.4 million, reflecting the management's commitment to investing in future technologies[24] - The company plans to establish a new high-tech enterprise focused on implant technology development within three years to enhance domestic product offerings[35] - The company aims to enhance R&D investment and innovation, introducing high-value-added products to meet the growing demand in dental healthcare and rehabilitation[183] Financial Position and Assets - The cash balance as of December 31, 2021, was approximately HKD 259.3 million, up from HKD 176.6 million in the previous year[50] - As of December 31, 2021, the equity attributable to shareholders was approximately HKD 651,100,000, an increase from HKD 636,500,000 in 2020[54] - The net current assets as of December 31, 2021, were approximately HKD 313,800,000, up from HKD 239,600,000 in 2020, with current and quick ratios of 2.20 and 2.14 respectively[54] - The company had no debt net amount as of December 31, 2021, indicating no capital debt ratio calculation[54] Operational Developments - The group generated revenue of approximately RMB 3.72 million (around HKD 4.49 million) from the first sports rehabilitation clinic, and RMB 1.66 million (around HKD 2 million) from the second clinic[28] - The group invested a total of RMB 180 million (approximately HKD 220.4 million) in limited partnership investments, focusing on information technology and quality healthcare sectors[31] - The group is actively exploring the "agriculture (culture) tourism + health" model in the Zhuhai project, which is currently under orderly construction[27] Corporate Governance - The board believes effective corporate governance is crucial for maintaining development and enhancing shareholder value[93] - The company has complied with the new corporate governance code effective from January 1, 2022, with some exceptions noted[93] - The board consists of a balanced mix of executive and independent non-executive directors, ensuring compliance with listing rules[101] - The company has established three committees: the nomination committee, remuneration committee, and audit committee, each with defined terms of reference[130] Risk Management and Compliance - The company has established multiple risk management procedures and guidelines, with the board conducting an annual review of the effectiveness of the risk management and internal control systems[146] - The internal control review indicated that significant risks threatening the achievement of business objectives have been identified and assessed[146] - The company has implemented policies for the handling and disclosure of inside information to ensure compliance with securities regulations[148] Environmental, Social, and Governance (ESG) - The ESG report aims to transparently disclose the group's performance in environmental, social, and governance aspects over the past year[172] - The company aims to integrate sustainability into its dental and health business development, recognizing the importance of ESG strategies in decision-making[181] - The company emphasizes energy conservation, greenhouse gas reduction, and providing a safe and healthy work environment for employees as part of its corporate social responsibility[185] - The company has established a comprehensive ESG framework, with various departments responsible for implementing ESG initiatives and evaluating reports[185] Employee and Stakeholder Engagement - The company conducted 67 meetings with approximately 1,067 employees during the reporting period[191] - A total of 400 interviews were held with 300 customers during the reporting period[192] - The company recognizes the importance of stakeholder communication and has set up various channels to address stakeholder feedback effectively[189]
佳兆业健康(00876) - 2021 - 中期财报
2021-09-28 08:55
Financial Performance - Revenue for the six months ended June 30, 2021, was HKD 103,275,000, an increase of 35.6% compared to HKD 76,175,000 for the same period in 2020[13] - Gross profit for the same period was HKD 54,058,000, representing a gross margin of 52.3%[13] - The net profit attributable to equity holders for the six months was HKD 60,666,000, compared to a loss of HKD 6,053,000 in the prior year[15] - Basic and diluted earnings per share for the period were HKD 1.20, a significant improvement from a loss of HKD 0.12 per share in the previous year[15] - Total comprehensive income for the period was HKD 65,279,000, compared to a loss of HKD 14,695,000 in the same period last year[15] - The company reported a fair value gain on financial assets of HKD 47,609,000, up from HKD 10,086,000 in the previous year[13] - The company experienced a foreign exchange gain of HKD 7,090,000, compared to a loss of HKD 8,366,000 in the previous year[15] - Total revenue for the six months ended June 30, 2021, was HKD 103,275,000, with HKD 100,441,000 from the dental business and HKD 2,834,000 from the health business[42] - The operating profit before depreciation and amortization for the dental business was HKD 15,280,000, while for the health business it was HKD 40,090,000, resulting in a total operating profit of HKD 55,370,000[42] - The total segment operating profit was HKD 42,890,000, with HKD 5,844,000 from the dental segment and HKD 37,046,000 from the health segment[42] Assets and Liabilities - Non-current assets increased to HKD 169,338,000 as of June 30, 2021, compared to HKD 425,069,000 as of December 31, 2020[17] - Current assets rose to HKD 743,546,000 as of June 30, 2021, up from HKD 332,470,000 at the end of 2020[17] - Total liabilities as of June 30, 2021, were HKD 162,661,000, with reportable segment liabilities of HKD 60,720,000 for the dental business and HKD 101,244,000 for the health business[47] - The company’s total liabilities decreased to HKD 148,110,000 as of June 30, 2021, from HKD 92,827,000 at the end of 2020[17] - The company’s inventory increased to HKD 7,951,000 as of June 30, 2021, compared to HKD 6,729,000 at the end of 2020[17] - The company’s total assets less current liabilities amounted to HKD 764,774,000 as of June 30, 2021, compared to HKD 664,712,000 at the end of 2020[17] Cash Flow - Cash and cash equivalents increased significantly to HKD 239,762,000 from HKD 176,600,000 year-over-year[23] - Net cash generated from operating activities was HKD 52,320,000 for the six months ended June 30, 2021, compared to a cash outflow of HKD 21,064,000 in the same period of 2020[23] - The company reported a net cash inflow from investing activities of HKD 8,842,000 for the first half of 2021, a recovery from a cash outflow of HKD 23,110,000 in the previous year[23] Segment Information - The company operates in two segments: manufacturing and trading of dental products and health business[38] - Revenue generated from external customers for the dental business was HKD 75,138,000 and for the health business was HKD 1,037,000, totaling HKD 76,175,000[3] - The company reported a loss before tax of HKD 6,494,000 for the health business, while the dental business generated a profit of HKD 914,000[3] Research and Development - Research and development expenses amounted to HKD 8,892,000, slightly down from HKD 9,187,000 in the previous year[54] - The company has applied for a tax deduction of 175% on research and development expenses for the taxable profits for the six months ended June 30, 2021, under a new policy effective from September 2019[59] Investments and Acquisitions - The company has entered into a cooperation agreement to invest in a subsidiary for the development of a health industry project in Zhuhai, China, with a 55% ownership stake[66] - The company plans to develop a comprehensive hospital project with 2,000 beds, focusing on organ transplantation and precision medical services[87] - The company entered into an agreement to acquire Basic Dental Implant Systems, Inc., which holds regulatory approvals and intellectual property related to dental implant systems in the U.S.[152] Shareholder Information - The company has not declared or recommended any dividends for the six months ended June 30, 2021, nor since the reporting date[60] - The issued and fully paid share capital as of June 30, 2021, was HKD 6,303,000, unchanged from December 31, 2020[115] - The total number of issued ordinary shares as of June 30, 2021, was 5,042,139,374, unchanged from December 31, 2020[186] Market and Strategic Outlook - Future outlook includes continued expansion in market presence and potential new product developments, although specific figures were not disclosed[13] - The company plans to expand its sales network both domestically and internationally, particularly in the U.S., and enhance production capacity for high-end dental products[165] - The dental market in China exceeded RMB 115 billion in 2020, with significant growth potential driven by increasing consumer spending and dental service demand[165] Miscellaneous - The company adopted revised Hong Kong Financial Reporting Standards effective January 1, 2021, which did not have a significant impact on the financial performance and position for the current and prior periods[36] - The company has not confirmed any losses from its investment in Hangzhou Jinyun for the six months ended June 30, 2021, amounting to approximately HKD 518,000[69] - The company has incurred a cumulative unrecognized loss of approximately HKD 982,000 from its investment in the associate Hangzhou Jinyun Investment Management Co., Ltd. as of June 30, 2021[69]
佳兆业健康(00876) - 2020 - 年度财报
2021-04-30 08:01
& Kaisa Health Group Holdings Limited 佳 兆 業 健 康 集 團 控 股 有 限 公 司 (Incorporated in Bermuda with limited liability 於百慕逵註冊成立之有限公司) (Stock Code 股份代號: 876) Annual Report 2020 年報 " ●● 000 目錄 公司資料 行政總裁報告 3 管理層討論及分析 6 董事及高層管理人員履歷 14 企業管治報告 18 環境、社會及管治報告 34 董事會報告 59 獨立核數師報告 77 綜合損益及其他全面收益表 83 綜合財務狀況表 85 綜合權益變動表 87 綜合現金流量表 88 綜合財務報表附註 90 2 財務概要 160 公司資料 董事 執行董事 2 佳兆業健康集團控股有限公司 年報2020 張華綱先生(主席) 羅軍先生(聯席副主席兼行政總裁) 武天逾先生(聯席副主席) 郭英成先生 獨立非執行董事 劉彥文博士 呂愛平博士 李永蘭女士 審核委員會 劉彥文博士(主席) 呂愛平博士 李永蘭女士 薪酬委員會 呂愛平博士(主席) 武天逾先生 劉彥文博士 提名委員會 張華 ...